| Year |
Citation |
Score |
| 2024 |
Diven MA, Tshering L, Ma X, Hu JC, Barbieri C, McClure T, Nagar H. Trends in Active Surveillance for Men With Intermediate-Risk Prostate Cancer. Jama Network Open. 7: e2429760. PMID 39172448 DOI: 10.1001/jamanetworkopen.2024.29760 |
0.374 |
|
| 2024 |
Pornour M, Jeon HY, Ryu H, Khadka S, Xu R, Chen H, Hussain A, Lam HM, Zhuang Z, Oo HZ, Gleave M, Dong X, Wang Q, Barbieri C, Qi J. USP11 promotes prostate cancer progression by up-regulating AR and c-Myc activity. Proceedings of the National Academy of Sciences of the United States of America. 121: e2403331121. PMID 39052835 DOI: 10.1073/pnas.2403331121 |
0.34 |
|
| 2024 |
Serio RN, Scheben A, Lu B, Gargiulo DV, Patruno L, Buckholtz CL, Chaffee RJ, Jibilian MC, Persaud SG, Staklinski SJ, Hassett R, Brault LM, Ramazzotti D, Barbieri CE, Siepel AC, et al. Clonal Lineage Tracing with Somatic Delivery of Recordable Barcodes Reveals Migration Histories of Metastatic Prostate Cancer. Cancer Discovery. PMID 38969342 DOI: 10.1158/2159-8290.CD-23-1332 |
0.336 |
|
| 2024 |
Sutera P, Song Y, Shetty AC, English K, Van der Eecken K, Guler OC, Wang J, Cao Y, Bazyar S, Verbeke S, Van Dorpe J, Fonteyne V, De Laere B, Mishra M, Rana Z, ... ... Barbieri C, et al. Genomic Determinants Associated with Modes of Progression and Patterns of Failure in Metachronous Oligometastatic Castration-sensitive Prostate Cancer. European Urology Oncology. PMID 38862340 DOI: 10.1016/j.euo.2024.05.011 |
0.335 |
|
| 2024 |
Augello MA, Chen X, Liu D, Lin K, Hakansson A, Sjöström M, Khani F, Deonarine LD, Liu Y, Travascio-Green J, Wu J, Loda M, Feng FY, Robinson BD, Davicioni E, ... ... Barbieri CE, et al. Canonical AREs are tumor suppressive regulatory elements in the prostate. Biorxiv : the Preprint Server For Biology. PMID 38464162 DOI: 10.1101/2024.02.23.581466 |
0.384 |
|
| 2024 |
Pakula H, Omar M, Carelli R, Pederzoli F, Fanelli GN, Pannellini T, Socciarelli F, Van Emmenis L, Rodrigues S, Fidalgo-Ribeiro C, Nuzzo PV, Brady NJ, Dinalankara W, Jere M, Valencia I, ... ... Barbieri CE, et al. Distinct mesenchymal cell states mediate prostate cancer progression. Nature Communications. 15: 363. PMID 38191471 DOI: 10.1038/s41467-023-44210-1 |
0.368 |
|
| 2023 |
Benedetti E, Chetnik K, Flynn T, Barbieri CE, Scherr DS, Loda M, Krumsiek J. Plasma metabolomics profiling of 580 patients from an Early Detection Research Network prostate cancer cohort. Scientific Data. 10: 830. PMID 38007532 DOI: 10.1038/s41597-023-02750-7 |
0.406 |
|
| 2023 |
Qureshy SA, Diven MA, Ma X, Marciscano AE, Hu JC, McClure TD, Barbieri C, Nagar H. Differential Use of Radiotherapy Fractionation Regimens in Prostate Cancer. Jama Network Open. 6: e2337165. PMID 37815829 DOI: 10.1001/jamanetworkopen.2023.37165 |
0.392 |
|
| 2023 |
Geng C, Zhang MC, Manyam GC, Vykoukal JV, Fahrmann JF, Peng S, Wu C, Park S, Kondraganti S, Wang D, Robinson BD, Loda M, Barbieri CE, Yap TA, Corn PG, et al. SPOP mutations target STING1 signaling in prostate cancer and create therapeutic vulnerabilities to PARP inhibitor-induced growth suppression. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 37581614 DOI: 10.1158/1078-0432.CCR-23-1439 |
0.415 |
|
| 2023 |
Arenas-Gallo C, Rhodes S, Garcia JA, Weinstein I, Prunty M, Lewicki P, Brant A, Basourakos SP, Barbieri CE, Lifschutz N, Schumacher FR, Shoag JE. Prostate cancer genetic alterations in Hispanic men. The Prostate. PMID 37301735 DOI: 10.1002/pros.24586 |
0.373 |
|
| 2023 |
Pakula H, Omar M, Carelli R, Pederzoli F, Fanelli GN, Pannellini T, Van Emmenis L, Rodrigues S, Fidalgo-Ribeiro C, Nuzzo PV, Brady NJ, Jere M, Unkenholz C, Alexanderani MK, Khani F, ... ... Barbieri CE, et al. Distinct mesenchymal cell states mediate prostate cancer progression. Biorxiv : the Preprint Server For Biology. PMID 37034687 DOI: 10.1101/2023.03.29.534769 |
0.439 |
|
| 2023 |
Jeon HY, Pornour M, Ryu H, Khadka S, Xu R, Jang J, Li D, Chen H, Hussain A, Fazli L, Gleave M, Dong X, Huang F, Wang Q, Barbieri C, et al. SMAD3 promotes expression and activity of the androgen receptor in prostate cancer. Nucleic Acids Research. PMID 36727462 DOI: 10.1093/nar/gkad043 |
0.369 |
|
| 2022 |
Brady NJ, Barbieri CE. JAK inhibition shows two faces in prostate cancer. Nature Cancer. 3: 1021-1023. PMID 36138136 DOI: 10.1038/s43018-022-00437-3 |
0.372 |
|
| 2022 |
Arenas-Gallo C, Owiredu J, Weinstein I, Lewicki P, Basourakos SP, Vince R, Al Hussein Al Awamlh B, Schumacher FR, Spratt DE, Barbieri CE, Shoag JE. Race and prostate cancer: genomic landscape. Nature Reviews. Urology. 19: 547-561. PMID 35945369 DOI: 10.1038/s41585-022-00622-0 |
0.395 |
|
| 2022 |
Brant A, Lewicki P, Wu X, Sze C, Johnson JP, Basourakos SP, Arenas-Gallo C, Shoag D, Barbieri CE, Zaorsky NG, Shoag JE. Impact of Left-digit Age Bias in the Treatment of Localized Prostate Cancer. The Journal of Urology. 101097JU000000000000. PMID 35900150 DOI: 10.1097/JU.0000000000002857 |
0.302 |
|
| 2022 |
Agrawal V, Ma X, Hu JC, Barbieri CE, Nagar H. Trends in Androgen Deprivation Use in Men With Intermediate-Risk Prostate Cancer Who Underwent Radiation Therapy. Advances in Radiation Oncology. 7: 100904. PMID 35814856 DOI: 10.1016/j.adro.2022.100904 |
0.347 |
|
| 2022 |
Basourakos SP, Gulati R, Vince RA, Spratt DE, Lewicki PJ, Hill A, Nyame YA, Cullen J, Markt SC, Barbieri CE, Hu JC, Trapl E, Shoag JE. Harm-to-Benefit of Three Decades of Prostate Cancer Screening in Black Men. Nejm Evidence. 1. PMID 35721307 DOI: 10.1056/evidoa2200031 |
0.358 |
|
| 2022 |
Cai PY, Asad M, Augello MA, Martin L, Louie C, Basourakos SP, Gaffney CD, Shoag J, Tu JJ, Khani F, Mosquera JM, Loda M, Scherr DS, Barbieri CE, Robinson BD. A multidisciplinary approach to optimize primary prostate cancer biobanking. Urologic Oncology. PMID 35490048 DOI: 10.1016/j.urolonc.2022.03.015 |
0.364 |
|
| 2022 |
Fontugne J, Cai PY, Alnajar H, Bhinder B, Park K, Ye H, Beg S, Sailer V, Siddiqui J, Blattner-Johnson M, Croyle JA, Noorzad Z, Calagua C, MacDonald TY, Axcrona U, ... ... Barbieri CE, et al. Collision tumors revealed by prospectively assessing subtype-defining molecular alterations in 904 individual prostate cancer foci. Jci Insight. 7. PMID 35050902 DOI: 10.1172/jci.insight.155309 |
0.373 |
|
| 2021 |
Mukhopadhyay C, Yang C, Xu L, Liu D, Wang Y, Huang D, Deonarine LD, Cyrta J, Davicioni E, Sboner A, Robinson BD, Chinnaiyan AM, Rubin MA, Barbieri CE, Zhou P. G3BP1 inhibits Cul3 to amplify AR signaling and promote prostate cancer. Nature Communications. 12: 6662. PMID 34795264 DOI: 10.1038/s41467-021-27024-x |
0.4 |
|
| 2021 |
Schumacher FR, Basourakos SP, Lewicki PJ, Vince R, Spratt DE, Barbieri CE, Shoag JE. Race and Genetic Alterations in Prostate Cancer. Jco Precision Oncology. 5. PMID 34746633 DOI: 10.1200/po.21.00324 |
0.375 |
|
| 2021 |
Grbesa I, Augello MA, Liu D, McNally DR, Gaffney CD, Huang D, Lin K, Ivenitsky D, Goueli R, Robinson BD, Khani F, Deonarine LD, Blattner M, Elemento O, Davicioni E, ... ... Barbieri CE, et al. Reshaping of the androgen-driven chromatin landscape in normal prostate cells by early cancer drivers and effect on therapeutic sensitivity. Cell Reports. 36: 109625. PMID 34496233 DOI: 10.1016/j.celrep.2021.109625 |
0.413 |
|
| 2021 |
Basourakos SP, Tzeng M, Lewicki PJ, Patel K, Awamlh BAHA, Venkat S, Shoag JE, Gorin MA, Barbieri CE, Hu JC. Tissue-Based Biomarkers for the Risk Stratification of Men With Clinically Localized Prostate Cancer. Frontiers in Oncology. 11: 676716. PMID 34123846 DOI: 10.3389/fonc.2021.676716 |
0.389 |
|
| 2021 |
Balasubramanian A, Nagar H, Barbieri CE, Tagawa ST, McClure TD. Re: Early Results of Unilateral Prostatic Artery Embolization as a Focal Therapy in Patients with Prostate Cancer under Active Surveillance: Cancer Prostate Embolization, a Pilot Study. Journal of Vascular and Interventional Radiology : Jvir. PMID 34091024 DOI: 10.1016/j.jvir.2021.05.021 |
0.389 |
|
| 2021 |
Liu D, Augello MA, Grbesa I, Prandi D, Liu Y, Shoag JE, Karnes RJ, Trock BJ, Klein EA, Den RB, Demichelis F, Davicioni E, Sboner A, Barbieri CE. Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer. The Journal of Clinical Investigation. 131. PMID 33998599 DOI: 10.1172/JCI147878 |
0.354 |
|
| 2021 |
Gaffney C, Liu D, Cooley V, Ma X, Angulo C, Robinson B, Khani F, Cai P, Salami S, Nallandhighal S, Shoag J, Barbieri C. Tumor size and genomic risk in localized prostate cancer. Urologic Oncology. PMID 33563537 DOI: 10.1016/j.urolonc.2021.01.020 |
0.389 |
|
| 2021 |
Cai PY, Ma X, Christos P, Barbieri CE, Shoag JE. Understanding the True Prevalence of Prostate Cancer Genomic Subtypes: Use of Inverse Probability Weighting to Correct for Biases in Molecularly Profiled Cohorts. The Journal of Urology. 101097JU000000000000. PMID 33502239 DOI: 10.1097/JU.0000000000001627 |
0.353 |
|
| 2020 |
Ben-Salem S, Hu Q, Liu Y, Alshalalfa M, Zhao X, Wang I, Venkadakrishnan VB, Senapati D, Kumari S, Liu D, Sboner A, Barbieri CE, Feng F, Billaud JN, Davicioni E, et al. Diversity in Androgen Receptor Action Among Treatment-naïve Prostate Cancers Is Reflected in Treatment Response Predictions and Molecular Subtypes. European Urology Open Science. 22: 34-44. PMID 33299986 DOI: 10.1016/j.euros.2020.10.002 |
0.34 |
|
| 2020 |
Adams EJ, Karthaus WR, Hoover E, Liu D, Gruet A, Zhang Z, Cho H, DiLoreto R, Chhangawala S, Liu Y, Watson PA, Davicioni E, Sboner A, Barbieri CE, Bose R, et al. Author Correction: FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes. Nature. PMID 32895534 DOI: 10.1038/S41586-020-2678-X |
0.452 |
|
| 2020 |
Agrawal V, Ma X, Hu JC, Barbieri CE, Nagar H. Trends in Diagnosis and Disparities in Initial Management of High-Risk Prostate Cancer in the US. Jama Network Open. 3: e2014674. PMID 32865572 DOI: 10.1001/jamanetworkopen.2020.14674 |
0.331 |
|
| 2020 |
Agrawal V, Ma X, Hu JC, Barbieri CE, Nagar H. Active Surveillance for Men with Intermediate Risk Prostate Cancer. The Journal of Urology. 101097JU000000000000. PMID 32658588 DOI: 10.1097/Ju.0000000000001241 |
0.486 |
|
| 2020 |
Marciscano AE, Barbieri CE. CDK12 Gene Alterations in Prostate Cancer: Present, but Clinically Actionable? European Urology. PMID 32381460 DOI: 10.1016/J.Eururo.2020.04.007 |
0.484 |
|
| 2020 |
Liu D, Shoag JE, Poliak D, Goueli RS, Ravikumar V, Redmond D, Vosoughi A, Fontugne J, Pan H, Lee D, Thomas D, Salari K, Wang Z, Romanel A, Te A, ... ... Barbieri CE, et al. Integrative multiplatform molecular profiling of benign prostatic hyperplasia identifies distinct subtypes. Nature Communications. 11: 1987. PMID 32332823 DOI: 10.1038/S41467-020-15913-6 |
0.47 |
|
| 2020 |
Shoag J, Liu D, Ma X, Oromendia C, Christos P, Ballman K, Angulo C, Cai PY, Gaffney C, Klein E, Karnes J, Den RB, Liu Y, Davicioni E, Barbieri CE. Prognostic value of the SPOP mutant genomic subclass in prostate cancer. Urologic Oncology. PMID 32192889 DOI: 10.1016/J.Urolonc.2020.02.011 |
0.487 |
|
| 2020 |
Mahase SS, D'Angelo D, Kang J, Hu JC, Barbieri CE, Nagar H. Trends in the Use of Stereotactic Body Radiotherapy for Treatment of Prostate Cancer in the United States. Jama Network Open. 3: e1920471. PMID 32022878 DOI: 10.1001/jamanetworkopen.2019.20471 |
0.349 |
|
| 2020 |
Shoag J, Cai* P, Gaffney C, Al Hussein Al Awamlh B, Ma X, Barbieri C. MP64-07 AGE-DEPENDENT PREVALENCE OF PROSTATE CANCER GENOMIC SUBTYPES PREDICTED BY INVERSE PROBABILITY WEIGHTING The Journal of Urology. 203: e965. DOI: 10.1097/Ju.0000000000000939.07 |
0.439 |
|
| 2020 |
Gaffney* C, Liu D, Angulo C, Cai P, Salami S, Nallandhighal S, Barbieri C, Shoag J. MP51-03 PROSTATE TUMOR SIZE IS INDEPENDENTLY ASSOCIATED WITH GENOMIC RISK The Journal of Urology. 203: e764. DOI: 10.1097/Ju.0000000000000913.03 |
0.417 |
|
| 2020 |
Cai* P, Alnajar H, Fontugne J, Gaffney C, Shoag J, Barbieri C, Mosquera JM. MP51-01 PREVALENCE OF COLLISION TUMORS IN PROSTATE CANCER AS A MODEL FOR INTRAFOCAL GENOMIC HETEROGENEITY The Journal of Urology. 203: e763. DOI: 10.1097/Ju.0000000000000913.01 |
0.478 |
|
| 2019 |
Persi E, Prandi D, Wolf YI, Pozniak Y, Barnabas GD, Levanon K, Barshack I, Barbieri C, Gasperini P, Beltran H, Faltas BM, Rubin MA, Geiger T, Koonin EV, Demichelis F, et al. Proteomic and genomic signatures of repeat instability in cancer and adjacent normal tissues. Proceedings of the National Academy of Sciences of the United States of America. PMID 31387980 DOI: 10.1073/Pnas.1908790116 |
0.339 |
|
| 2019 |
Berger A, Brady NJ, Bareja R, Robinson BD, Conteduca V, Augello MA, Puca L, Ahmed A, Dardenne E, Lu X, Hwang I, Bagadion AM, Sboner A, Elemento O, Paik J, ... ... Barbieri CE, et al. N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer. The Journal of Clinical Investigation. 130. PMID 31260412 DOI: 10.1172/Jci127961 |
0.492 |
|
| 2019 |
Adams EJ, Karthaus WR, Hoover E, Liu D, Gruet A, Zhang Z, Cho H, DiLoreto R, Chhangawala S, Liu Y, Watson PA, Davicioni E, Sboner A, Barbieri CE, Bose R, et al. FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes. Nature. PMID 31243370 DOI: 10.1038/S41586-019-1318-9 |
0.412 |
|
| 2019 |
Armenia J, Wankowicz SAM, Liu D, Gao J, Kundra R, Reznik E, Chatila WK, Chakravarty D, Han GC, Coleman I, Montgomery B, Pritchard C, Morrissey C, Barbieri CE, Beltran H, et al. Publisher Correction: The long tail of oncogenic drivers in prostate cancer. Nature Genetics. PMID 31152158 DOI: 10.1038/S41588-019-0451-6 |
0.456 |
|
| 2019 |
Khani F, Wobker SE, Hicks JL, Robinson BD, Barbieri CE, De Marzo AM, Epstein JI, Pritchard CC, Lotan TL. Intraductal Carcinoma of the Prostate in the Absence of High Grade Invasive Carcinoma Represents a Molecularly Distinct Type of in situ Carcinoma Enriched with Oncogenic Driver Mutations. The Journal of Pathology. PMID 30993692 DOI: 10.1002/Path.5283 |
0.438 |
|
| 2019 |
Shoag J, Liu D, Ma X, Oromendia C, Angulo C, Liu S, Liu Y, Davicioni E, Barbieri C. MP68-12 IMPACT OF SPOP MUTATION ON PROSTATE CANCER PROGNOSIS. The Journal of Urology. 201: e979-e980. PMID 30950719 DOI: 10.1097/01.Ju.0000557027.87083.D3 |
0.5 |
|
| 2019 |
Gaffney C, Golan R, Cantu MD, Scognamiglio T, McCarthy H, Mosquera JM, McClure TD, Barbieri CE, Robinson BD, Khani F. The Clinical Utility of the Genomic Prostate Score in Men with Very Low to Intermediate Risk Prostate Cancer. The Journal of Urology. 101097JU000000000000. PMID 30933552 DOI: 10.1097/Ju.0000000000000170 |
0.466 |
|
| 2019 |
Augello MA, Liu D, Deonarine LD, Robinson BD, Huang D, Stelloo S, Blattner M, Doane AS, Wong EWP, Chen Y, Rubin MA, Beltran H, Elemento O, Bergman AM, Zwart W, ... ... Barbieri CE, et al. CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis. Cancer Cell. PMID 30930119 DOI: 10.1016/J.Ccell.2019.03.001 |
0.481 |
|
| 2019 |
Shoag JE, Tosoian JJ, Salami SS, Barbieri CE. Unraveling Prostate Cancer Genomics, Pathology, and Magnetic Resonance Imaging Visibility. European Urology. PMID 30712974 DOI: 10.1016/J.Eururo.2019.01.027 |
0.416 |
|
| 2019 |
Nagar H, Formenti S, Scherr D, Hu JC, Schlegel P, Kang J, Robinson BD, Khani F, Nanus DM, Tagawa ST, Molina AM, Faltas BM, Margolis D, Barbieri C. Preoperative radiotherapy for high-risk prostate cancer (PORT-PC) trial. Journal of Clinical Oncology. 37: TPS137-TPS137. DOI: 10.1200/Jco.2019.37.7_Suppl.Tps137 |
0.407 |
|
| 2019 |
Vlachostergios PJ, Schaap A, Sun M, Sternberg CN, Molina AM, Nanus DM, Barbieri C, Tagawa ST. Multi-gene hereditary cancer testing, family history and prognosis in men with prostate cancer. Journal of Clinical Oncology. 37: 5073-5073. DOI: 10.1200/Jco.2019.37.15_Suppl.5073 |
0.455 |
|
| 2019 |
Berger A, Brady N, Bareja R, Robinson B, Conteduca V, Augello M, Puca L, Ahmed A, Lu X, Hwang I, Bagadion A, Sboner A, Elemento O, Paik J, Yu J, ... Barbieri C, et al. Abstract 2099: N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-2099 |
0.477 |
|
| 2018 |
Liu D, Takhar M, Alshalalfa M, Erho N, Shoag J, Jenkins RB, Karnes RJ, Ross AE, Schaeffer EM, Rubin MA, Trock B, Klein EA, Den RB, Tomlins SA, Spratt DE, ... ... Barbieri CE, et al. Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer. Jco Precision Oncology. 2018. PMID 30761387 DOI: 10.1200/PO.18.00036 |
0.406 |
|
| 2018 |
Elfandy H, Armenia J, Pederzoli F, Pullman E, Pértega-Gomes N, Schultz N, Viswanathan K, Vosoughi A, Blattner M, Stopsack KH, Zadra G, Penney KL, Mosquera JM, Tyekucheva S, Mucci LA, ... Barbieri C, et al. Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate. Molecular Cancer Research : McR. PMID 30333152 DOI: 10.1158/1541-7786.Mcr-18-0440 |
0.474 |
|
| 2018 |
Boysen G, Nava Rodrigues D, Rescigno P, Seed G, Dolling DI, Riisnaes R, Crespo M, Zafeiriou Z, Sumanasuriya S, Bianchini D, Hunt J, Moloney D, Perez-Lopez R, Tunariu N, Miranda S, ... ... Barbieri CE, et al. SPOP mutated/ CHD1 deleted lethal prostate cancer and abiraterone sensitivity. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30068710 DOI: 10.1158/1078-0432.Ccr-18-0937 |
0.47 |
|
| 2018 |
Barbieri CE. Introduction to "Molecular drivers of prostate cancer development, progression, and resistance to therapy". Urologic Oncology. 36: 367. PMID 30064932 DOI: 10.1016/J.Urolonc.2018.06.003 |
0.45 |
|
| 2018 |
Arora K, Barbieri CE. Molecular Subtypes of Prostate Cancer. Current Oncology Reports. 20: 58. PMID 29858674 DOI: 10.1007/S11912-018-0707-9 |
0.448 |
|
| 2018 |
Armenia J, Wankowicz SAM, Liu D, Gao J, Kundra R, Reznik E, Chatila WK, Chakravarty D, Han GC, Coleman I, Montgomery B, Pritchard C, Morrissey C, Barbieri CE, Beltran H, et al. The long tail of oncogenic drivers in prostate cancer. Nature Genetics. PMID 29610475 DOI: 10.1038/S41588-018-0078-Z |
0.529 |
|
| 2018 |
Rescigno P, Boysen G, Nava Rodrigues D, Seed G, Dolling D, Riisnaes R, Crespo M, Bianchini D, Sumanasuriya S, Figueiredo I, Christova R, Gil V, Goodall J, Sharp A, Rubin MA, ... ... Barbieri C, et al. Molecular and clinical implications of CHD1 loss and SPOP mutations in advanced prostate cancer. Journal of Clinical Oncology. 36: 5064-5064. DOI: 10.1200/Jco.2018.36.15_Suppl.5064 |
0.485 |
|
| 2018 |
Cantu M, Golan R, McCarthy H, Scognamiglio T, McClure T, Barbieri C, Robinson B, Khani F. MP17-06 UTILITY OF ONCOTYPE DX IN MEN WITH INTERMEDIATE-RISK PROSTATE CANCER Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.561 |
0.469 |
|
| 2017 |
Shoag J, Liu D, Blattner M, Sboner A, Park K, Deonarine L, Robinson BD, Mosquera JM, Chen Y, Rubin MA, Barbieri CE. SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG. The Journal of Clinical Investigation. PMID 29202479 DOI: 10.1172/Jci96551 |
0.525 |
|
| 2017 |
Golombos DM, Ayangbesan A, O'Malley P, Lewicki P, Barlow L, Barbieri CE, Chan C, DuLong C, Abu-Ali G, Huttenhower C, Scherr DS. The Role of Gut Microbiome in the Pathogenesis of Prostate Cancer: a Prospective, Pilot Study. Urology. PMID 28888753 DOI: 10.1016/J.Urology.2017.08.039 |
0.497 |
|
| 2017 |
Shoag J, Savenkov O, Christos PJ, Mittal S, Halpern JA, Askin G, Shoag D, Golan R, Lee DJ, O'Malley P, Najari B, Eisner B, Hu JC, Scherr D, Schlegel P, ... Barbieri CE, et al. Vasectomy and Risk of Prostate Cancer in a Screening Trial. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 28830873 DOI: 10.1158/1055-9965.Epi-16-0776 |
0.485 |
|
| 2017 |
Wang H, Barbieri CE, He J, Gao Y, Shi T, Wu C, Schepmoes AA, Fillmore TL, Chae SS, Huang D, Mosquera JM, Qian WJ, Smith RD, Srivastava S, Kagan J, et al. Quantification of mutant SPOP proteins in prostate cancer using mass spectrometry-based targeted proteomics. Journal of Translational Medicine. 15: 175. PMID 28810879 DOI: 10.1186/S12967-017-1276-7 |
0.479 |
|
| 2017 |
Dai X, Gan W, Li X, Wang S, Zhang W, Huang L, Liu S, Zhong Q, Guo J, Zhang J, Chen T, Shimizu K, Beca F, Blattner M, Vasudevan D, ... ... Barbieri CE, et al. Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. Nature Medicine. PMID 28805820 DOI: 10.1038/Nm.4378 |
0.526 |
|
| 2017 |
Lee D, Fontugne J, Gumpeni N, Park K, MacDonald TY, Robinson BD, Sboner A, Rubin MA, Mosquera JM, Barbieri CE. Molecular alterations in prostate cancer and association with MRI features. Prostate Cancer and Prostatic Diseases. PMID 28762374 DOI: 10.1038/Pcan.2017.33 |
0.46 |
|
| 2017 |
Dutta A, Panja S, Virk RK, Kim JY, Zott R, Cremers S, Golombos DM, Liu D, Mosquera JM, Mostaghel EA, Barbieri CE, Mitrofanova A, Abate-Shen C. Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5α-reductase Inhibition. European Urology. PMID 28385453 DOI: 10.1016/J.Eururo.2017.03.031 |
0.464 |
|
| 2017 |
Blattner M, Liu D, Robinson BD, Huang D, Poliakov A, Gao D, Nataraj S, Deonarine LD, Augello MA, Sailer V, Ponnala L, Ittmann M, Chinnaiyan AM, Sboner A, Chen Y, ... ... Barbieri CE, et al. SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling. Cancer Cell. 31: 436-451. PMID 28292441 DOI: 10.1016/J.Ccell.2017.02.004 |
0.515 |
|
| 2017 |
O'Malley PG, Nguyen DP, Al Awamlh BA, Wu G, Thompson IM, Sanda M, Rubin M, Wei JT, Lee R, Christos P, Barbieri C, Scherr DS. Racial variation in the utility of urinary biomarkers, PCA3 and T2ERG, in a large, multicenter study. The Journal of Urology. PMID 28115190 DOI: 10.1016/J.Juro.2017.01.058 |
0.423 |
|
| 2017 |
Shoag J, Liu D, Blattner M, Sboner A, Mosquera JM, Robinson B, Chen Y, Barbieri C. MP99-08 SPOP MUTANT PROSTATE CANCER IS NOT DRIVEN BY ERG STABILIZATION Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.3094 |
0.484 |
|
| 2017 |
Stone BV, Shoag J, Barbieri CE, Hu JC, Lee RK. Accurate Estimation of Prostate Size in the Evaluation of Nocturia Current Bladder Dysfunction Reports. 12: 113-117. DOI: 10.1007/S11884-017-0420-9 |
0.379 |
|
| 2016 |
Lewicki P, Shoag J, Golombos DM, Oromendia C, Ballman KV, Halpern JA, Stone BV, O'Malley P, Barbieri CE, Scherr DS. Prognostic significance of a negative prostate biopsy: An analysis of subjects enrolled in a prostate cancer screening trial. The Journal of Urology. PMID 27836710 DOI: 10.1016/J.Juro.2016.11.002 |
0.474 |
|
| 2016 |
Mateo J, Boysen G, Barbieri CE, Bryant HE, Castro E, Nelson PS, Olmos D, Pritchard CC, Rubin MA, de Bono JS. DNA Repair in Prostate Cancer: Biology and Clinical Implications. European Urology. PMID 27590317 DOI: 10.1016/J.Eururo.2016.08.037 |
0.433 |
|
| 2016 |
Stone BV, Shoag J, Halpern JA, Mittal S, Lewicki P, Golombos DM, Bedretdinova D, Chughtai B, Barbieri CE, Lee RK. Prostate size, nocturia, and the digital rectal exam: a cohort study of 30,500 men. Bju International. PMID 27480499 DOI: 10.1111/Bju.13613 |
0.419 |
|
| 2016 |
Shoag J, Mittal S, Halpern JA, Scherr D, Hu JC, Barbieri CE. Lethal Prostate Cancer in the PLCO Cancer Screening Trial. European Urology. PMID 27166670 DOI: 10.1016/J.Eururo.2016.01.009 |
0.389 |
|
| 2016 |
Shoag J, Barbieri CE. Clinical variability and molecular heterogeneity in prostate cancer. Asian Journal of Andrology. PMID 27080479 DOI: 10.4103/1008-682X.178852 |
0.492 |
|
| 2016 |
Shoag J, Halpern JA, Lee DJ, Mittal S, Ballman KV, Barbieri CE, Hu JC. Decline in prostate cancer screening by primary care physicians: an analysis of trends in the use of digital rectal examination and prostate specific antigen testing. The Journal of Urology. PMID 27060052 DOI: 10.1016/J.Juro.2016.03.171 |
0.455 |
|
| 2016 |
Kaffenberger SD, Barbieri CE. Molecular subtyping of prostate cancer. Current Opinion in Urology. PMID 26986650 DOI: 10.1097/Mou.0000000000000285 |
0.506 |
|
| 2016 |
Shoag J, Barbieri C. Clinical variability and molecular heterogeneity in prostate cancer Asian Journal of Andrology. 18: 543-548. DOI: 10.4103/1008-682X.178852 |
0.397 |
|
| 2016 |
Boysen G, Rodrigues DN, Mateo J, Christova R, Riisnaes R, Crespo M, MacDonald T, Miranda S, Figueiredo I, Gil V, Aziz S, Sharp A, Mehra N, Rescigno P, Mosquera JM, ... Barbieri CE, et al. Abstract 4976: Monitoring CHD1 during prostate cancer progression Cancer Research. 76: 4976-4976. DOI: 10.1158/1538-7445.Am2016-4976 |
0.534 |
|
| 2016 |
Blattner M, Liu D, Huang D, Gao D, Sboner A, Chen Y, Rubin MA, Barbieri C. Abstract 4174: SPOP mutation drives tumorigenesis in mouse prostate - a novel model of ETS negative prostate cancer Cancer Research. 76: 4174-4174. DOI: 10.1158/1538-7445.Am2016-4174 |
0.483 |
|
| 2016 |
Wang H, Barbieri C, He J, Gao Y, Wu C, Schepmoes A, Fillmore T, Shi T, Chae S, Huang D, Mosquera JM, Qian W, Smith R, Srivastava S, Kagan J, et al. Abstract 3872: Quantification of mutant SPOP proteins in prostate cancer using targeted proteomics Cancer Research. 76: 3872-3872. DOI: 10.1158/1538-7445.Am2016-3872 |
0.468 |
|
| 2016 |
Vasudevan D, Blattner M, Deonarine LD, Chen Y, Rubin MA, Barbieri CE. Abstract 3672: Coordinated roles of CHD1 and SPOP in prostate cancer pathogenesis Cancer Research. 76: 3672-3672. DOI: 10.1158/1538-7445.Am2016-3672 |
0.541 |
|
| 2016 |
Augello MA, Blattner-Johnson M, Rubin M, Barbieri C. Abstract 1974: Consequence of the tumor-associated deletion of CHD1 on transcriptional output and tumor progression Cancer Research. 76: 1974-1974. DOI: 10.1158/1538-7445.Am2016-1974 |
0.493 |
|
| 2016 |
O'Malley P, Golombos DM, Lewicki P, Al Awamlh BAH, Christos PJ, Thompson IM, Sanda MG, Wei JT, Rubin MA, Barbieri CE, Scherr DS. MP21-12 PCA3 AND T2:ERG ADD FURTHER PREDICTIVE AND CLINICAL BENEFIT TO THE DETECTION OF PROSTATE CANCER IN MEN OF VARIOUS AGES IN THE EARLY DETECTION RESEARCH NETWORK (EDRN) Journal of Urology. 195. DOI: 10.1016/S1569-9056(16)60388-3 |
0.333 |
|
| 2016 |
Najari B, Lee D, Shoag J, Park K, He B, Mosquera JM, Rubin M, Schlegel P, Barbieri C. MP62-10 TMPRSS2-ERG GENE FUSION IS AN UNCOMMON SOMATIC ALTERATION IN HYPOGONADAL MEN WITH PROSTATE CANCER Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.918 |
0.536 |
|
| 2016 |
Shoag J, Kasabwala K, Mittal S, Halpern J, Lee D, Hu J, Barbieri C. MP25-10 DECLINE IN PROSTATE SPECIFIC ANTIGEN SCREENING AMONG PRIMARY CARE PHYSICIANS IN RESPONSE TO UNITED STATES PREVENTATIVE SERVICES TASK FORCE RECOMMENDATIONS Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.787 |
0.324 |
|
| 2016 |
Shoag J, Mittal S, Halpern J, Shoag D, Lee D, O'Malley P, Najari B, Eisner B, Hu J, Scherr D, Schlegel P, Barbieri C. MP91-12 VASECTOMY AND RISK OF PROSTATE CANCER IN A SCREENING TRIAL Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.2599 |
0.437 |
|
| 2016 |
Lee D, Golombos D, O'Malley P, Liu D, Sboner A, Goueli R, Patel N, Kim S, Kasabwala K, Scherr D, Barbieri C. MP04-16 CLINICAL ASSOCIATIONS WITH PROSTATE CANCER MOLECULAR FEATURES IN THE CANCER GENOME ATLAS (TCGA) DATA. Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.1951 |
0.469 |
|
| 2016 |
Stone B, Shoag J, Bedretdinova D, Mittal S, Halpern J, Lewicki P, Forde J, Barbieri C, Chughtai B, Li P, Lee R. MP35-05 DIGITAL RECTAL EXAM AND PROSTATE SIZE FOR THE EVALUATION OF BENIGN PROSTATE PATHOLOGY: AN ANALYSIS OF 30,500 MEN PRESENTING FOR SCREENING EXAMS IN THE PLCO CANCER SCREENING TRIAL Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.1597 |
0.348 |
|
| 2016 |
Shoag J, Mittal S, Halpern J, Scherr D, Hu J, Barbieri C. PD15-05 LETHAL PROSTATE CANCER IN THE PLCO CANCER SCREENING TRIAL Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.1131 |
0.421 |
|
| 2015 |
Haffner MC, Barbieri CE. Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia. European Urology. PMID 26651925 DOI: 10.1016/J.Eururo.2015.11.020 |
0.485 |
|
| 2015 |
Boysen G, Barbieri CE, Prandi D, Blattner M, Chae SS, Dahija A, Nataraj S, Huang D, Marotz C, Xu L, Huang J, Lecca P, Chhangawala S, Liu D, Zhou P, et al. SPOP mutation leads to genomic instability in prostate cancer. Elife. 4. PMID 26374986 DOI: 10.7554/Elife.09207 |
0.478 |
|
| 2015 |
Shoag J, Halpern J, Eisner B, Lee R, Mittal S, Barbieri CE, Shoag D. Efficacy of Prostate-Specific Antigen Screening: Use of Regression Discontinuity in the PLCO Cancer Screening Trial. Jama Oncology. 1: 984-986. PMID 26291583 DOI: 10.1001/Jamaoncol.2015.2993 |
0.4 |
|
| 2015 |
Barbieri CE, Tomlins SA. Reprint of: The prostate cancer genome: Perspectives and potential. Urologic Oncology. 33: 95-102. PMID 25726356 DOI: 10.1016/J.Urolonc.2015.01.002 |
0.505 |
|
| 2015 |
Barbieri CE, Rubin MA. Genomic rearrangements in prostate cancer. Current Opinion in Urology. 25: 71-6. PMID 25393273 DOI: 10.1097/Mou.0000000000000129 |
0.473 |
|
| 2015 |
Miyahira AK, Kissick HT, Bishop JL, Takeda DY, Barbieri CE, Simons JW, Pienta KJ, Soule HR. Beyond immune checkpoint blockade: new approaches to targeting host-tumor interactions in prostate cancer: report from the 2014 Coffey-Holden prostate cancer academy meeting. The Prostate. 75: 337-47. PMID 25358693 DOI: 10.1002/Pros.22920 |
0.48 |
|
| 2015 |
Boysen G, Barbieri CE, Prandi D, Blattner M, Chae S, Dahija A, Nataraj S, Huang D, Marotz C, Xu L, Huang J, Lecca P, Chhangawala S, Liu D, Zhou P, et al. Author response: SPOP mutation leads to genomic instability in prostate cancer Elife. DOI: 10.7554/Elife.09207.026 |
0.471 |
|
| 2015 |
Barbieri CE, Boysen G, Prandi D, Chae S, Dahiya A, Nataraj S, Blattner M, Marotz C, Xu L, Huang J, Lecca P, Chhangawala S, Zhou P, Sboner A, Demichelis F, et al. Abstract NG01: SPOP mutation is associated with genomic instability in prostate cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Ng01 |
0.504 |
|
| 2015 |
Boysen G, Barbieri CE, Prandi D, Chae S, Nataraj S, Blattner M, Marotz C, Xu L, Lecca P, Chhangawala S, Zou P, Sboner A, Demichelis F, Houvras Y, Rubin MA. Abstract 1108: SPOP mutation leads to genomic instability in prostate cancer Cancer Research. 75: 1108-1108. DOI: 10.1158/1538-7445.Am2015-1108 |
0.503 |
|
| 2015 |
Lee D, Fontugne J, Gumpeni N, Park K, MacDonald T, Robinson B, Sboner A, Mosquera JM, Rubin M, Barbieri C. MP17-12 MOLECULAR ALTERATIONS IN PROSTATE CANCER AND ASSOCIATION WITH MRI FEATURES Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.854 |
0.465 |
|
| 2015 |
O'Malley P, Al Hussein Al Awamlh B, Nguyen DP, Sanda MG, Thompson IM, Wei JT, Lee R, Rubin MA, Barbieri CE, Hermann MP, Scherr DS. MP6-02 LOCATION OF DISEASE DOES NOT IMPACT PCA3'S ABILITY TO PREDICT CANCER ON BIOPSY Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.249 |
0.351 |
|
| 2015 |
Barbieri C, Boysen G, Prandi D, Chae S, Dahiya A, Nataraj S, Blattner M, Marotz C, Xu L, Huang J, Lecca P, Chhangawala S, Zhou P, Sboner A, Demichelis F, et al. MP66-01 SPOP MUTATION LEADS TO GENOMIC INSTABILITY IN PROSTATE CANCER Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.2354 |
0.483 |
|
| 2015 |
O'Malley P, Al Hussein Al Awamlh B, Sarkisian AM, Jin S, Nguyen DP, Lee R, Scherr DS, Barbieri CE, Hermann MP. MP83-04 POTENTIAL FOR FAILURE OF FOCAL PROSTATE HEMI-ABLATION STRATEGIES Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.1879 |
0.416 |
|
| 2015 |
Abeshouse A, Ahn J, Akbani R, Ally A, Amin S, Andry CD, Annala M, Aprikian A, Armenia J, Arora A, Auman JT, Balasundaram M, Balu S, Barbieri CE, Bauer T, et al. The Molecular Taxonomy of Primary Prostate Cancer Cell. 163: 1011-1025. DOI: 10.1016/j.cell.2015.10.025 |
0.398 |
|
| 2014 |
Prandi D, Baca SC, Romanel A, Barbieri CE, Mosquera JM, Fontugne J, Beltran H, Sboner A, Garraway LA, Rubin MA, Demichelis F. Unraveling the clonal hierarchy of somatic genomic aberrations. Genome Biology. 15: 439. PMID 25160065 DOI: 10.1186/S13059-014-0439-6 |
0.381 |
|
| 2014 |
Khani F, Mosquera JM, Park K, Blattner M, O'Reilly C, MacDonald TY, Chen Z, Srivastava A, Tewari AK, Barbieri CE, Rubin MA, Robinson BD. Evidence for molecular differences in prostate cancer between African American and Caucasian men. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 4925-34. PMID 25056375 DOI: 10.1158/1078-0432.Ccr-13-2265 |
0.481 |
|
| 2014 |
Otto B, Barbieri C, Lee R, Te AE, Kaplan SA, Robinson B, Chughtai B. Incidental prostate cancer in transurethral resection of the prostate specimens in the modern era. Advances in Urology. 2014: 627290. PMID 24876835 DOI: 10.1155/2014/627290 |
0.487 |
|
| 2014 |
Blattner M, Lee DJ, O'Reilly C, Park K, MacDonald TY, Khani F, Turner KR, Chiu YL, Wild PJ, Dolgalev I, Heguy A, Sboner A, Ramazangolu S, Hieronymus H, Sawyers C, ... ... Barbieri CE, et al. SPOP mutations in prostate cancer across demographically diverse patient cohorts. Neoplasia (New York, N.Y.). 16: 14-20. PMID 24563616 DOI: 10.1593/Neo.131704 |
0.473 |
|
| 2014 |
Fontugne J, Lee D, Cantaloni C, Barbieri CE, Caffo O, Hanspeter E, Mazzoleni G, Dalla Palma P, Rubin MA, Fellin G, Mosquera JM, Barbareschi M, Demichelis F. Recurrent prostate cancer genomic alterations predict response to brachytherapy treatment. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 23: 594-600. PMID 24515272 DOI: 10.1158/1055-9965.Epi-13-1180 |
0.51 |
|
| 2014 |
Barbieri CE, Demichelis F, Rubin MA. The lethal clone in prostate cancer: redefining the index. European Urology. 66: 395-7. PMID 24411284 DOI: 10.1016/J.Eururo.2013.12.052 |
0.464 |
|
| 2014 |
Park K, Dalton JT, Narayanan R, Barbieri CE, Hancock ML, Bostwick DG, Steiner MS, Rubin MA. TMPRSS2:ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 206-11. PMID 24297949 DOI: 10.1200/Jco.2013.49.8386 |
0.467 |
|
| 2014 |
Barbieri CE, Tomlins SA. The prostate cancer genome: perspectives and potential. Urologic Oncology. 32: 53.e15-22. PMID 24239470 DOI: 10.1016/J.Urolonc.2013.08.025 |
0.505 |
|
| 2014 |
Barbieri CE, Rubin MA. Molecular characterization of prostate cancer following androgen deprivation: the devil in the details. European Urology. 66: 40-1. PMID 24011425 DOI: 10.1016/J.Eururo.2013.08.056 |
0.441 |
|
| 2014 |
Fontugne J, Lee D, Cantaloni C, Barbieri CE, Orazio C, Hanspeter E, Mazzoleni G, Palma PD, Rubin MA, Fellin G, Mosquera JM, Barbareschi M, Demichelis F. Abstract 3952: Recurrent prostate cancer genomic alterations predict response to brachytherapy treatment Cancer Research. 74: 3952-3952. DOI: 10.1158/1538-7445.Am2014-3952 |
0.488 |
|
| 2014 |
Fontugne J, Lee D, Cantaloni C, Barbieri C, Caffo O, Hanspeter E, Mazzoleni G, Palma PD, Rubin M, Fellin G, Mosquera JM, Barbareschi M, Demichelis F. MP24-13 WITHDRAWN: RECURRENT PROSTATE CANCER GENOMIC ALTERATIONS PREDICT RESPONSE TO BRACHYTHERAPY TREATMENT Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.294 |
0.463 |
|
| 2014 |
Blattner M, Lee D, O'Reilly C, Park K, MacDonald T, Khani F, Turner K, Chiu Y, Wild P, Sboner A, Ramazangolu S, Hieronymus H, Sawyers C, Tewari A, Andren O, ... ... Barbieri C, et al. MP41-06 SPOP MUTATIONS IN PROSTATE CANCER ACROSS DEMOGRAPHICALLY DIVERSE PATIENT COHORTS. Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.1223 |
0.496 |
|
| 2013 |
Barbieri CE. Evolution of novel biomarkers for detection of prostate cancer. The Journal of Urology. 190: 1970-1. PMID 24045221 DOI: 10.1016/J.Juro.2013.09.018 |
0.478 |
|
| 2013 |
Barbieri CE, Bangma CH, Bjartell A, Catto JW, Culig Z, Grönberg H, Luo J, Visakorpi T, Rubin MA. The mutational landscape of prostate cancer. European Urology. 64: 567-76. PMID 23759327 DOI: 10.1016/J.Eururo.2013.05.029 |
0.459 |
|
| 2013 |
Barbieri CE, Sboner A, Rubin MA, Garraway LA. Re: Stoehr et al. Lack of evidence for frequent MED12 p.L1224F mutation in prostate tumours from Caucasian patients. J Pathol 2013; 230: 453-456. The Journal of Pathology. 231: 271. PMID 23729306 DOI: 10.1002/Path.4216 |
0.394 |
|
| 2013 |
Baca SC, Prandi D, Lawrence MS, Mosquera JM, Romanel A, Drier Y, Park K, Kitabayashi N, MacDonald TY, Ghandi M, Van Allen E, Kryukov GV, Sboner A, Theurillat JP, Soong TD, ... ... Barbieri CE, et al. Punctuated evolution of prostate cancer genomes. Cell. 153: 666-77. PMID 23622249 DOI: 10.1016/J.Cell.2013.03.021 |
0.517 |
|
| 2013 |
Geng C, He B, Xu L, Barbieri CE, Eedunuri VK, Chew SA, Zimmermann M, Bond R, Shou J, Li C, Blattner M, Lonard DM, Demichelis F, Coarfa C, Rubin MA, et al. Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover. Proceedings of the National Academy of Sciences of the United States of America. 110: 6997-7002. PMID 23559371 DOI: 10.1073/Pnas.1304502110 |
0.473 |
|
| 2013 |
Baca SC, Prandi D, Lawrence MS, Mosquera JM, Romanel A, Drier Y, Park K, Kitabayashi N, MacDonald TY, Allen EV, Kryukov GV, Theurillat J, Soong TD, Nickerson E, Auclair D, ... ... Barbieri CE, et al. Abstract 4601: Punctuated evolution of prostate cancer genomes. Cancer Research. 73: 4601-4601. DOI: 10.1158/1538-7445.Am2013-4601 |
0.512 |
|
| 2013 |
Prandi D, Baca SC, Lawrence MS, Mosquera JM, Romanel A, Drier Y, Park K, Kitabayashi N, MacDonald TY, Allen EV, Kryukov GV, Theurillat J, Soong TD, Nickerson E, Auclair D, ... ... Barbieri CE, et al. Abstract 4017: Dissecting the clonal hierarchy of cancer-driving genomic lesions. Cancer Research. 73: 4017-4017. DOI: 10.1158/1538-7445.Am2013-4017 |
0.38 |
|
| 2013 |
Barbieri C, Blattner M, Xu L, Demichelis F, Baca S, Lawrence M, Boysen G, Theurillat J, Tewari A, Zhou P, Garraway L, Rubin M. 200 DEFINING THE MECHANISTIC BASIS OF SPOP MUTATIONS IN PROSTATE CANCER Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.1580 |
0.49 |
|
| 2012 |
Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP, White TA, Stojanov P, Van Allen E, Stransky N, Nickerson E, Chae SS, Boysen G, Auclair D, Onofrio RC, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nature Genetics. 44: 685-9. PMID 22610119 DOI: 10.1038/Ng.2279 |
0.528 |
|
| 2012 |
Esgueva R, Park K, Kim R, Kitabayashi N, Barbieri CE, Dorsey PJ, Abraham C, Banerjee S, Leung RA, Tewari AK, Terry S, Shevchuk MM, Rickman DS, Rubin MA. Next-generation prostate cancer biobanking: toward a processing protocol amenable for the International Cancer Genome Consortium. Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B. 21: 61-8. PMID 22555088 DOI: 10.1097/Pdm.0B013E31823B6Da6 |
0.427 |
|
| 2012 |
Barbieri CE, Demichelis F, Rubin MA. Molecular genetics of prostate cancer: emerging appreciation of genetic complexity. Histopathology. 60: 187-98. PMID 22212086 DOI: 10.1111/J.1365-2559.2011.04041.X |
0.384 |
|
| 2012 |
Barbieri CE, Baca SC, Lawrence MS, Getz G, Rubin MA, Garraway LA. Abstract IA13: Recurrent SPOP mutations define a distinct molecular subclass of prostate cancer Cancer Research. 72. DOI: 10.1158/1538-7445.Prca2012-Ia13 |
0.52 |
|
| 2012 |
Boysen G, Bourque C, Huang J, Barbieri C, Kitabayashi N, Chen Z, Demichelis F, Hussain W, Houvras Y, Rubin M. 593 Modeling Prostate Cancer Oncogenesis Through Developmental Alterations in Zebrafish European Journal of Cancer. 48: S141-S142. DOI: 10.1016/S0959-8049(12)71250-9 |
0.398 |
|
| 2012 |
Barbieri C, Chughtai B, Te AE, Kaplan SA, Robinson B, Lee R. 2018 INCIDENTAL PROSTATE CANCER IN TRANSURETHRAL RESECTION OF THE PROSTATE (TURP) IN THE MODERN ERA Journal of Urology. 187. DOI: 10.1016/J.Juro.2012.02.2181 |
0.49 |
|
| 2012 |
Barbieri C, Baca S, Demichelis F, Lawrence M, Blattner M, Theurillat J, Boysen G, Stojanov P, Van Allen E, Stransky N, Nickerson E, Park K, Kitabayashi N, MacDonald T, Vuong T, et al. 1314 RECURRENT MUTATIONS IN SPOP DEFINE A DISTINCT MOLECULAR CLASS OF PROSTATE CANCER Journal of Urology. 187. DOI: 10.1016/J.Juro.2012.02.1661 |
0.477 |
|
| 2011 |
Shariat SF, Chromecki TF, Hoefer J, Barbieri CE, Scherr DS, Karakiewicz PI, Roehrborn CG, Montorsi F, Culig Z, Cavarretta IT. Soluble gp130 regulates prostate cancer invasion and progression in an interleukin-6 dependent and independent manner. The Journal of Urology. 186: 2107-14. PMID 21944124 DOI: 10.1016/J.Juro.2011.06.048 |
0.491 |
|
| 2011 |
Barbieri CE, Demichelis F, Grasso C, Vuong T, MacDonald T, Boysen G, Banerjee S, Kitabayashi N, Berger MF, Tewari AK, Garraway LA, Chinnaiyan AM, Rubin MA. Abstract LB-246: Recurrent inactivating mutations in SPOP define a molecular subset of prostate cancer Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-246 |
0.535 |
|
| 2011 |
Shariat S, Chromecki T, Hoefer J, Barbieri C, Scherr D, Karakiewicz P, Roehrborn C, Montorsi F, Culig Z, Cavarretta I. 2335 SOLUBLE GP130 PROMOTES PROSTATE CANCER INVASION AND PROGRESSION IN AN IL-6 INDEPENDENT FASHION Journal of Urology. 185. DOI: 10.1016/J.Juro.2011.02.2582 |
0.435 |
|
| 2011 |
Barbieri C, Boysen G, Demichelis F, Vuong T, Berger M, Kitabayashi N, Tewari A, Grasso C, Chinnaiyan A, Garraway L, Rubin M. 608 COMBINING DNA-SEQ AND RNA-SEQ FOR DISCOVERY OF NOVEL MUTATIONS IN HUMAN PROSTATE CANCER Journal of Urology. 185. DOI: 10.1016/J.Juro.2011.02.1461 |
0.387 |
|
| 2009 |
Barton CE, Tahinci E, Barbieri CE, Johnson KN, Hanson AJ, Jernigan KK, Chen TW, Lee E, Pietenpol JA. DeltaNp63 antagonizes p53 to regulate mesoderm induction in Xenopus laevis. Developmental Biology. 329: 130-9. PMID 19272371 DOI: 10.1016/J.Ydbio.2009.02.036 |
0.686 |
|
| 2006 |
Barbieri CE, Tang LJ, Brown KA, Pietenpol JA. Loss of p63 leads to increased cell migration and up-regulation of genes involved in invasion and metastasis. Cancer Research. 66: 7589-97. PMID 16885358 DOI: 10.1158/0008-5472.Can-06-2020 |
0.604 |
|
| 2006 |
Hinow P, Rogers CE, Barbieri CE, Pietenpol JA, Kenworthy AK, DiBenedetto E. The DNA binding activity of p53 displays reaction-diffusion kinetics. Biophysical Journal. 91: 330-42. PMID 16603489 DOI: 10.1529/Biophysj.105.078303 |
0.545 |
|
| 2006 |
Barbieri CE, Pietenpol JA. p63 and epithelial biology. Experimental Cell Research. 312: 695-706. PMID 16406339 DOI: 10.1016/J.Yexcr.2005.11.028 |
0.622 |
|
| 2005 |
Barbieri CE, Pietenpol JA. p53 family members: similar biochemistry, different biology. Cancer Biology & Therapy. 4: 419-20. PMID 15908776 DOI: 10.4161/Cbt.4.4.1760 |
0.568 |
|
| 2005 |
Westfall MD, Joyner AS, Barbieri CE, Livingstone M, Pietenpol JA. Ultraviolet radiation induces phosphorylation and ubiquitin-mediated degradation of DeltaNp63alpha. Cell Cycle (Georgetown, Tex.). 4: 710-6. PMID 15846104 DOI: 10.4161/Cc.4.5.1685 |
0.731 |
|
| 2005 |
Barbieri CE, Perez CA, Johnson KN, Ely KA, Billheimer D, Pietenpol JA. IGFBP-3 is a direct target of transcriptional regulation by DeltaNp63alpha in squamous epithelium. Cancer Research. 65: 2314-20. PMID 15781645 DOI: 10.1158/0008-5472.Can-04-3449 |
0.672 |
|
| 2003 |
Barbieri CE, Barton CE, Pietenpol JA. Delta Np63 alpha expression is regulated by the phosphoinositide 3-kinase pathway. The Journal of Biological Chemistry. 278: 51408-14. PMID 14555649 DOI: 10.1074/Jbc.M309943200 |
0.654 |
|
| 2003 |
Matheny KE, Barbieri CE, Sniezek JC, Arteaga CL, Pietenpol JA. Inhibition of epidermal growth factor receptor signaling decreases p63 expression in head and neck squamous carcinoma cells. The Laryngoscope. 113: 936-9. PMID 12782800 DOI: 10.1097/00005537-200306000-00004 |
0.57 |
|
| Show low-probability matches. |